Company profile for Omeros

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We have taken a similar approach in structuring our company. While many biotechs pursue a single therapeutic area or scientific platform, we are strategically building a deep and diverse pipeline of first-in-class small-molecule and antibody therapeutics. The strength of our scientific discoveries and exclusive intellectual property positions enable our pipeline programs to target highly promising receptors and enzymes that ot...
We have taken a similar approach in structuring our company. While many biotechs pursue a single therapeutic area or scientific platform, we are strategically building a deep and diverse pipeline of first-in-class small-molecule and antibody therapeutics. The strength of our scientific discoveries and exclusive intellectual property positions enable our pipeline programs to target highly promising receptors and enzymes that others have not been able to develop.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
The Omeros Building, 201 Elliott Avenue, West Seattle, WA 98119
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251201875667/en/Omeros-Corporation-Announces-Closing-of-Asset-Purchase-and-License-Agreement-with-Novo-Nordisk-for-Omeros-Clinical-Stage-MASP-3-Inhibitor-Zaltenibart-OMS906

BUSINESSWIRE
01 Dec 2025

https://www.businesswire.com/news/home/20251113632270/en/Omeros-Corporation-Reports-Third-Quarter-2025-Financial-Results

BUSINESSWIRE
13 Nov 2025

https://www.businesswire.com/news/home/20251111937325/en/Omeros-Corporation-to-Announce-Third-Quarter-Financial-Results-on-November-13-2025

BUSINESSWIRE
11 Nov 2025

https://www.businesswire.com/news/home/20251016675834/en/Omeros-Announces-Publication-Highlighting-Survival-Benefits-in-TA-TMA-Patients-Treated-with-Narsoplimab-Versus-a-Well-Matched-External-Control-Group

BUSINESSWIRE
16 Oct 2025

https://www.fiercebiotech.com/biotech/novo-nordisk-pens-21b-deal-omeros-stalled-pnh-drug

FIERCE BIOTECH
15 Oct 2025

https://www.fiercebiotech.com/biotech/fda-delays-omeros-2nd-attempt-transplant-drugs-approval-3-months

FIERCE BIOTECH
18 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty